Research Analysts Issue Forecasts for PLX FY2027 Earnings

Key Points

• HC Wainwright lowered its FY2027 EPS forecast for Protalix BioTherapeutics to $0.11 from $0.12, while maintaining a “Buy” rating and a $12 price target. The firm expects $0.06 EPS in Q4 2027, compared with a current full-year consensus estimate of $0.01.
• PLX shares opened at $2.67, above their 50-day and 200-day moving averages of $2.42 and $2.33, respectively. The stock has traded between $1.60 and $3.19 over the past year, with a market capitalization of approximately $215 million.
• Institutional interest has increased: BlackRock and Geode Capital Management initiated new positions, while Jane Street, Dimensional Fund Advisors, and Goldman Sachs significantly expanded their holdings. Institutional investors collectively own 16.53% of the company.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Analysts at HC Wainwright reduced their FY2027 earnings estimates for Protalix BioTherapeutics in a research note issued to investors on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.11 per share for the year, down from their previous estimate of $0.12. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q4 2027 earnings at $0.06 EPS.

Protalix BioTherapeutics Price Performance

PLX stock opened at $2.67 on Thursday. The business has a 50-day moving average price of $2.42 and a 200 day moving average price of $2.33. The company has a market capitalization of $215.13 million, a P/E ratio of -20.54 and a beta of 0.02. Protalix BioTherapeutics has a 1-year low of $1.60 and a 1-year high of $3.19.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter worth $9,429,000. Geode Capital Management LLC purchased a new position in Protalix BioTherapeutics in the second quarter valued at about $1,223,000. Jane Street Group LLC raised its holdings in Protalix BioTherapeutics by 894.3% in the fourth quarter. Jane Street Group LLC now owns 289,917 shares of the company's stock worth $522,000 after purchasing an additional 326,417 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Protalix BioTherapeutics by 932.7% in the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company's stock worth $644,000 after purchasing an additional 268,099 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Protalix BioTherapeutics by 482.3% during the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company's stock valued at $741,000 after buying an additional 239,751 shares during the last quarter. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics NYSE: PLX is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix's core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company's first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.